Addressing the Social Determinants of Health and Decreasing Disparities in PAH: A Focus on Technology, Practice-Changing Tools and Advancing Therapies


Vallerie V. McLaughlin, MD

Faculty Chair

Professor of Medicine

Director, Pulmonary Hypertension Program

University of Michigan Medical School

Ann Arbor, MI

Jean M. Elwing, MD


Professor of Medicine

Division of Pulmonary, Critical Care and Sleep Medicine

University of Cincinnati

Cincinnati, OH

Nicholas Kolaitis, MD, MAS


Assistant Professor

Pulmonary, Critical Care, Allergy and Sleep Medicine

University of California at San Francisco

San Francisco, CA

R. James White III, MD, PhD


Professor of Medicine, Pharmacology, and Physiology

School of Medicine and Dentistry

University of Rochester Medical Center

Rochester, NY

Program Overview

Many PAH patients remain undiscovered, undiagnosed, and underserved. The reasons for this are vast but central to the treatment of these patients is a need to make PAH care more accessible. The COVID-19 pandemic has further exacerbated the need to connect with not only with undiagnosed PAH patients, but even those currently under care. Part of the solution to these modern-day issues centers on reducing medical and ancillary costs to patients and making the most of telemedicine.

Through the lens of SDoH, we explore the rising prevalence of Methamphetamine-associated Pulmonary Arterial Hypertension (Meth-APAH) and the unique and unmet needs of patients and uncover how this phenotype differs in its characteristics and outcomes from idiopathic PAH.

Key themes brought to light in the program include the burdens many patients and healthcare providers face including financial costs of care and the prejudices many experience or perceive.

Target Audience

This educational initiative is designed for cardiologists, pulmonologists, critical care clinicians and primary care practitioners, including advanced practice clinicians (nurse practitioners and physician assistants) nurses and pharmacists.


The Social Determinants of Health and Developments in PAH

Credit Amount: 0.50

Credit Type: AMA

Expiration: 3/15/2024


Maintaining and Improving Access to PAH Care

Credit Amount: 0.50

Credit Type: AMA

Expiration: 3/21/204

This activity is jointly provided by Global Education Group and Iridium Continuing Education.
This educational activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and Merck Sharp & Dohme LLC.